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Introduction: Gastric cancer is the second most common cancer worldwide. The standard 
  treatment is radical surgical resection, but 60% of patients will present recurrence. TNM 
  classification (6th edition, American Joint Committee on Cancer) recommends the removal 
of at least 15 regional lymph nodes to carry out an adequate pathological staging. But in our 
  environment, only 20% of cases have the minimum recommended, so it would be very   important 
to have an alternative prognostic. We designed a retrospective study to evaluate different 
  prognostic factors in patients inadequately staged.
Material and methods: We focused on patients with serosal involvement (pT3). The 
evaluation included general parameters such as age, sex, tumor site, histological type, type of 
gastrectomy, histological grade, number of nodes analyzed ,/$ 10, lymph node ratio (LNR) 
with a 20% cutoff value, and adjuvant treatment. The association between clinicopathological 
variables and recurrence was investigated by univariate and multivariate logistic regression. It 
was considered statistically significant with P , 0.05.
Results: A total of 92 patients who met the criteria were studied. Median age 65 years; 68% 
men, 32% women; median follow-up time for the overall population, 44 months (range 15–119 
months); number of nodes analyzed, median 7 (range 0–14 nodes); recurrence in 59%; median 
time to recurrence, 15 months (range 3–48 months); the cumulative risk of relapse at five years, 
64%. Multivariate statistical analysis showed that the LNR (P = 0.03) and total number of nodes 
analyzed ,/$ 10 (P = 0.04) were independent predictors for the risk of recurrence.
Conclusion: LNR and total number of nodes analyzed with a threshold of 10 (,/$ 10 nodes 
analyzed) were independent predictors of recurrence in patients with gastric carcinoma pT3 
and an insufficient number of nodes examined.
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Introduction
Gastric cancer is the second most common cancer worldwide.1 Although there has 
been a trend of a decline in its incidence and mortality during the last decades, gastric 
cancer is still a relevant health problem around the world.2
Much effort has been made to improve its survival rate, although not much has been 
accomplished yet. The only potentially curative treatment for gastric cancer is radical 
surgery.1 Despite this, 60% of all these patients will relapse after complete resection;3 
this fact being the cause of its high mortality rate. Although one of the most important 
prognostic factors in this disease are the pathological staging after complete resection, 
considerable controversy has surrounded the concept of what defines an adequate 
lymphadenectomy for potentially curative treatment of gastric cancer.2Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Based on available published data, at least a D1 lymph-
adenectomy is recommended.2 In patients where there is a 
suspicion of N2 nodes, a D2 resection should be advised and 
should be performed by surgeons experienced with this tech-
nique.2 According to TNM Classification of Malignant Tumors 
(6th edition),4 at least 15 nodes should be removed and evaluated 
to carry out an adequate pathological staging and subsequently to 
  correctly divide patients into different prognostic subgroups.
Despite the lack of evidence, it would seem more benefi-
cial to apply treatments in an individualized way; so much 
effort has to be focused on the search for an effective adjuvant 
or preoperative therapy and to find the best prognostic factors 
to select better patients who are more likely to benefit from 
these treatments to improve cure rates.
Few studies have suggested the ratio of the number 
of involved lymph nodes among the overall lymph nodes 
removed as another independent prognostic factor, which is 
more important than the node status.5–7
Despite all these recommendations, only 20% of cases 
in our environment have the advised minimum of lymph 
nodes examined to carry out an accurate staging. This 
means there exists a high rate of understaged gastric cancer 
with the negative prognostic and therapeutic impact this 
fact could have.8,9 In this controversial context it would be 
very important to have alternative prognostic factors more 
related to recurrence risk in these understaged cases. With 
this aim, we developed a joint effort with General Surgery 
and Radiotherapy Oncology Departments in order to identify 
other clinicopathological factors as predictive of recurrence 
in patients undergoing gastric carcinoma surgery with less 
than 15 nodes evaluated. We focused only on patients with 
serosal involvement (pT3) in the histopathologycal analysis, 
because this subgroup was the most frequent (more than 70%) 
encountered between patients radically operated.
Material and methods
We designed a retrospective study with the aim described 
above. All patients with primary gastric adenocarcinoma 
were evaluated in this current study. Eligible patients were 
individuals older than 18 years of age, with citologically 
or histologically proved gastric adenocarcinoma who had 
  undergone radical surgery R0 according to the International 
Union Against Cancer. All these patients had less than 
15 nodes evaluated and wall depth of invasion was pT3 
according to TNM (6th edition). Patients with metastatic 
disease were excluded from our study.
This study was carried out at the Valladolid Clini-
cal   University Hospital between 2003 and 2006. The 
  clinicopathologic parameters such as age, sex, histologic type, 
grade of tumor site, type of gastrectomy, ,/$ 10 total lymph 
nodes evaluated, lymph node ratio (LNR, number of involved 
lymph nodes among the overall lymph nodes removed) keep-
ing a 20% cutoff value and adjuvant treatment. All these data 
were evaluated by reviewing medical charts and pathologic 
records. This study was approved by the Research Committee 
of our institution.
The association between all these clinicopathologic 
variables and recurrence was investigated by univariate 
and multivariate logistic regression analyses. Results were 
considered statistically significant when P values were less 
than 0.05. All statistical analyses were conducted using SPSS 
8.0 software package.
Results
We included 92 patients in this study with a median age of 
65 years (range 32–76 years). 68% were males and 32% 
females. All of them were from this geographical area and 
white race.
The median follow-up time for the overall population was 
44 months (range 15–119 months). The median number of nodes 
analyzed was 7 (range 0–14 nodes). 20% of our   population was 
N0, having 0 nodes analyzed the 14% of them.
64% of these patients didn’t receive any adjuvant treat-
ment (see Table 1).
Recurrence was detected in 59% of patients (total 
54 patients) with a median time to relapse of 15 months (range 
Table 1 Basal characteristics of included patients
N %
Sex Male 62 68
Female 30 32
Lauren type Intestinal 
Diffuse
55 
37
59 
41
Nodes Median 7
range 0–14
0 nodes analysed 13
Stage II (T3N0) 20 
26 
46
22 
28 
50
III-A (T3N1)
III-B (T3N2)
Age Median 65 years
range 32–76 years
Grade 1 17 18
2 34 36
3 41 46
Location Cardia/fundus 
Stomach 
34 
58
37 
63
Adjuvant treatment No
Chemotherapy
Chemoradiotherapy
59
10
23
64
11
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3–48 months). 11 of them were locoregional recurrences, 
7 cases presented distance metastases without locoregional 
relapse, and 36 showed both types of recurrences at the same 
time (see Table 2).
77% of recurrences occurred within the first 2 years 
after surgical treatment. The estimated cumulative risk of 
relapse at 5 years in our study population was 64%, which 
ranged between 85% and 46% respectively according to the 
LNR . and # 20%.
The univariate and multivariate statistical analysis 
revealed that the LNR (odds ratio [OR] 2.14, 95% confi-
dence interval [CI]: 1.02–5.58, P = 0.03) and total number 
of nodes analyzed ,/$ 10 (OR 2.75, 95% CI: 1.5–8.21, 
P = 0.04) were independent predictors of recurrence in 
these patients.
Discussion
Gastric cancer still represents one of the most important 
causes of cancer-related morbidity and mortality around the 
world.2 Although much effort has been made to improve its 
prognosis, it remains with a high mortality rate which seems 
difficult to reduce.2
Many studies indicate that nodal involvement is one of 
the most important factors in determining the prognosis of 
patients with gastric carcinoma undergoing radical surgery, 
and it is significantly associated with the submucosal and 
serosal invasion of tumor cells.8 American Joint   Committee 
on Cancer/Union International against cancer (AJCC/
UICC) TNM classification (6th edition) recommends 
the evaluation of at least 15 nodes to achieve an optimal 
  staging.4 This is essential to accurately establish prognostic 
subgroups; however, in current clinical practice most cases 
could be understaged due to an inadequate number of lymph 
nodes retrieved. This fact has lead to search more accurate 
  prognostic factors to better target the multidisciplinary 
therapy of these patients.
Previous studies have suggested that the LNR, which 
is defined as the ratio of the number of metastatic lymph 
nodes to the total number of nodes dissected, is a powerful 
independent prognostic factor with significant superiority 
over more traditional factors.3,5–7 Although those studies 
have reported different cutoff values for LNR without having 
reached consensus, the most common one has been 20%. In 
all these studies, an extended lymphadenectomy (D2),2 which 
is associated with a higher number of lymph nodes removed, 
was used as the standard surgical procedure; therefore, the 
issue of the prognostic value of the N ratio after D1 lymph 
node dissection has not been widely addressed. In the study 
by Marchet et al10 which addressed this point, the authors have 
concluded that N ratio is a simple and reproducible prognostic 
tool that can stratify patients with gastric cancer, also in case 
of limited lymph node dissection. These data may represent 
a good rationale for improving the prognostic power of cur-
rent UICC TNM staging system and ultimately the selection 
of patients who may most benefit from adjuvant treatments.
In our institution we have previously carried out another 
study with the aim of evaluating different predictive   factors 
for recurrence in patients inadequately staged, and we 
obtained a significant relationship between the depth of tumor 
involvement/LNR and the recurrence risk.9
Encouraged by these results and since more than 70% 
of our patients have serosal involvement (traditionally 
  considered T3), we have decided to also evaluate the   different 
clinicopathologic parameters and their relationship with the 
recurrence risk in this population.
We have studied 92 patients that had undergone a   radical 
surgery in our institution. Although all of them had less 
than 15 nodes evaluated we obtained interesting results. 
The total number of nodes analyzed with a threshold of 10 
(,/$ 10 nodes analyzed) was an independent predictor of 
recurrence in these patients. We have decided the threshold 
of 10 nodes based on our previous study evaluating the 
clinicopathologic predictors of nodal metastases in patients 
undergoing radical resection. It is known that the higher 
the number of examined nodes, the higher the likelihood of 
involvement. Our results showed that invasion depth of tumor 
and number of lymph nodes examined (,/$ 6 and ,/$ 10) 
were independent predictors of nodal metastases.11 Based on 
these findings we tried to evaluate the same threshold in this 
specific   population (T3).
On the other hand we have also shown the relevance of 
LNR in these patients as a predictor of recurrence.11
Although there have been controversial findings related 
to the N ratio in different Western and Japanese series, this 
factor has been considered as an effective prognostic tool after 
D2 or D3 lymphadenectomy.12–18 In a study by Bando et al 
Table 2 recurrences in our study population
Total (%)
recurrence 54 (64%)
Time to recurrence
  Median 
  range
15 months 
3–48 months
Type of recurrence
  Locoregional 
  Distance 
  Both
11 (20%) 
7 (14%) 
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at multivariate analysis the N ratio was retained as the only 
independent prognostic factor when the number and the side 
of metastatic lymph nodes were considered,13 and similarly, 
Kunisaki et al recently reported that the N ratio independently 
influenced the prognosis of 758 patients radically resected.19
In this way, the majority of the published studies address-
ing the prognostic value of N ratio in patients with gastric can-
cer have considered only patients who underwent extended 
lymphadenectomy (and therefore more than 15 lymph nodes 
dissected), so the study by Marchet et al10 is very important 
because it is the first report evaluating and demonstrating the 
prognostic power of N ratio among patients with inadequate 
lymph node dissection.
Unlike the N classification, whose prognostic power is 
significantly affected by the number of removed lymph nodes, 
the N ratio could distinguish subsets of patients with similar 
prognosis as the study by Marchet et al has demonstrated.
Overall, all these findings underline the ability of N ratio 
classification to identify prognostically homogeneous 
subsets of patients. Despite these findings, the new TNM 
classification (7th edition)20 has suffered some modifica-
tions. Nowadays the old T3 has changed to T4a (a more 
advanced category), and N classification has been divided 
into 4   categories, although it continues considering just the 
number of nodes affected without taking into account the 
number of lymph nodes removed. Despite these changes 
more related with different prognostic subgroups, this new 
classification does not solve the problem of how to deal 
with patients inadequately staged. In these cases we think it 
would be relevant to consider the alternative of LNR to select 
patients according to recurrence risk.
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